ArticleBrain and behavior2026
Functional Brain Network Abnormalities and Aripiprazole's Modulatory Effects in Pediatric Tic Disorder.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study aimed to investigate functional brain network characteristics in pediatric tic disorder (TD) patients and explore the effects of aripiprazole treatment on the functional brain network.
methodsResting-state electroencephalogram (EEG) was recorded from 40 TD patients and 30 matched healthy controls to compare functional brain network differences between TD patients and healthy individuals. Additionally, 26 of these TD patients underwent a 12-week aripiprazole treatment and were evaluated for changes in their functional brain networks before and after treatment. Functional connectivity between brain regions was analyzed using the phase locking value (PLV), and global network topological properties (global efficiency, local efficiency, clustering coefficient, and characteristic path length) were quantified via graph theory.
resultsCompared with controls, TD patients exhibited reduced frontal functional connectivity (Fp2-Fz, Fp2-F4, Fz-F4) but compensatory enhanced connectivity in F7-F3 and C3-Cz. Tourette syndrome patients further exhibited Fp1-Fz hypo-connectivity. Aripiprazole treatment significantly increased global functional connectivity, elevated global and local efficiency and clustering coefficient, and shortened characteristic path length in TD patients. However, frontal hypo-connectivity persisted after treatment partly.
conclusionsPediatric TD patients present frontal dysfunction with compensatory adaptations in frontal-temporal connection and sensorimotor networks. Aripiprazole modulates global brain network connectivity and topology but not does not normalize frontal deficits, providing neurophysiological evidence for TD pathophysiology and aripiprazole's therapeutic mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.